Cargando…
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial
The effect of renal impairment (RI) on risk of bleeding and recurrent thrombosis in cancer patients treated with direct oral anticoagulants for venous thromboembolism (VTE) is undefined. We ran a prespecified analysis of the randomized Caravaggio study to evaluate the role of RI as a risk factor for...
Autores principales: | Becattini, Cecilia, Bauersachs, Rupert, Maraziti, Giorgio, Bertoletti, Laurent, Cohen, Alexander, Connors, Jean M., Manfellotto, Dario, Sanchez, Antonio, Brenner, Benjamin, Agnelli, Giancarlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244816/ https://www.ncbi.nlm.nih.gov/pubmed/34382385 http://dx.doi.org/10.3324/haematol.2021.279072 |
Ejemplares similares
-
Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study
por: Giustozzi, Michela, et al.
Publicado: (2021) -
Management of venous thromboembolism in patients with cancer: role of dalteparin
por: Linkins, Lori-Ann
Publicado: (2008) -
Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
por: Arce-Huamani, Miguel A., et al.
Publicado: (2023) -
Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study
por: Hill, Jason B., et al.
Publicado: (2020) -
Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism
por: Ward, Joey, et al.
Publicado: (2023)